ePrints

Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial

Lookup NU author(s): Professor David Jones

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Invernizzi P, Carbone M, Jones D, Levy C, Little N, Wiesel P, Nevens F

Publication type: Article

Publication status: Published

Journal: Liver International

Year: 2023

Volume: 43

Issue: 7

Pages: 1507-1522

Print publication date: 01/07/2023

Online publication date: 15/05/2023

Acceptance date: 15/04/2023

Date deposited: 18/09/2024

ISSN (print): 1478-3223

ISSN (electronic): 1478-3231

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1111/liv.15596

DOI: 10.1111/liv.15596

Data Access Statement: Study data, including individual participant data, will not be made available to others after publication. The study protocol is available at https://clinicaltrials.gov/ct2/show/study/NCT03226067. No additional related documents will be made available.

PubMed id: 37183520

Altmetrics

Funding

Share